Muna Therapeutics Appoints Dr. Niels Plath as Chief Scientific Officer

Muna Therapeutics (“Muna“), pioneering the development of novel, first-in-class small molecule therapeutics for neurodegenerative diseases, today announces the appointment of Dr. Niels Plath as Chief Scientific Officer.

Dr. Plath is a molecular biologist and neuroscientist with more than 15 years of experience in academia and biopharma. He was previously the acting Head of Global Research at Lundbeck, leading drug discovery and development for neurologic and psychiatric diseases. Prior to this role, Dr. Plath was Vice President for Neuroscience, leading teams that brought several drug candidates into clinical development, including alpha-synuclein and tau targeting antibodies, idalopirdine and Nalmefene.

Rita Balice-Gordon, Chief Executive Officer of Muna Therapeutics, said: “We are delighted to welcome Niels as Muna’s Chief Scientific Officer. He shares our commitment to discover and develop disease modifying therapeutics to address the staggering unmet need experienced by patients with neurodegenerative disorders around the world.”

Henrijette Richter, Managing Partner at Sofinnova Partners, said: “Niels has broad biopharma R&D experience that will be invaluable as Muna continues to progress its innovative pipeline of potential disease-modifying medicines for neurodegenerative diseases. We are very pleased to be supporting Muna’s world-class global team.”

Niels Plath, Chief Scientific Officer of Muna Therapeutics, said: “I’m excited to be joining Muna Therapeutics to further develop its promising, cutting-edge pipeline of neurodegenerative disease therapeutics. I’m looking forward to working with this stellar team to advance promising treatments for patients to significantly improve their quality of life.”

Dr. Plath obtained a PhD in Neuroscience from the Free University of Berlin, Germany, focusing on the role of immediate early genes in neuronal plasticity, learning and memory. Following a postdoctoral fellowship supported by the Human Frontier Science Program, he joined biopharma in 2005 to pursue research and development of treatments for patients with CNS disorders. Dr. Plath has authored many scientific publications in peer-reviewed journals, is a guest lecturer in Neuroscience at the University of Copenhagen and has given numerous conference talks at meetings around the world.